Business Description
Galapagos NV
ISIN : BE0003818359
Share Class Description:
WBO:GLPG: Ordinary SharesCompare
Compare
Traded in other countries / regions
GLPG.NetherlandsGLPG.USA0JXZ.UKGXE.GermanyGLPG.AustriaG1LP34.BrazilGLPG.BelgiumGLPG.Mexico IPO Date
2017-10-04Description
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 291.22 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.65 | |||||
| Beneish M-Score | 31.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -20.9 | |||||
| 3-Year EPS without NRI Growth Rate | 58.8 | |||||
| 3-Year FCF Growth Rate | 6.8 | |||||
| 3-Year Book Growth Rate | 1.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -73.96 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.26 | |||||
| 9-Day RSI | 41.78 | |||||
| 14-Day RSI | 43.2 | |||||
| 6-1 Month Momentum % | 2.73 | |||||
| 12-1 Month Momentum % | -22.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.13 | |||||
| Quick Ratio | 9.95 | |||||
| Cash Ratio | 9.51 | |||||
| Days Inventory | 1294.29 | |||||
| Days Sales Outstanding | 63 | |||||
| Days Payable | 2464.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.2 | |||||
| Shareholder Yield % | 0.41 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.65 | |||||
| Operating Margin % | -66.12 | |||||
| Net Margin % | 79.33 | |||||
| FCF Margin % | -158.37 | |||||
| ROE % | 7.32 | |||||
| ROA % | 4.77 | |||||
| ROIC % | -19.47 | |||||
| 3-Year ROIIC % | -1138.42 | |||||
| ROC (Joel Greenblatt) % | -48.8 | |||||
| ROCE % | -1.61 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 8.16 | |||||
| Forward PE Ratio | 156.25 | |||||
| PS Ratio | 6.46 | |||||
| PB Ratio | 0.59 | |||||
| Price-to-Tangible-Book | 0.64 | |||||
| EV-to-EBIT | 25.96 | |||||
| EV-to-EBITDA | 25.96 | |||||
| EV-to-Revenue | -6.32 | |||||
| EV-to-FCF | 3.99 | |||||
| Price-to-Projected-FCF | 0.5 | |||||
| Price-to-Median-PS-Value | 0.33 | |||||
| Price-to-Net-Current-Asset-Value | 0.75 | |||||
| Price-to-Net-Cash | 0.83 | |||||
| Earnings Yield (Greenblatt) % | 3.85 | |||||
| FCF Yield % | -24.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galapagos NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 260.094 | ||
| EPS (TTM) (€) | 3.13 | ||
| Beta | -0.02 | ||
| Volatility % | 23.62 | ||
| 14-Day RSI | 43.2 | ||
| 14-Day ATR (€) | 0.525125 | ||
| 20-Day SMA (€) | 26.578 | ||
| 12-1 Month Momentum % | -22.08 | ||
| 52-Week Range (€) | 22.06 - 38.74 | ||
| Shares Outstanding (Mil) | 65.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galapagos NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galapagos NV Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Galapagos NV Frequently Asked Questions
What is Galapagos NV(WBO:GLPG)'s stock price today?
The current price of WBO:GLPG is €25.52. The 52 week high of WBO:GLPG is €38.74 and 52 week low is €22.06.
When is next earnings date of Galapagos NV(WBO:GLPG)?
The next earnings date of Galapagos NV(WBO:GLPG) is 2025-02-23 Est..
Does Galapagos NV(WBO:GLPG) pay dividends? If so, how much?
Galapagos NV(WBO:GLPG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers